NASDAQ:ARGX 10 August 2025

ARGX Stock Watch: Argenx Up Ahead of Immunovant Trial Data
······

ARGX Stock Watch: Argenx Up Ahead of Immunovant Trial Data

argenx SE’s U.S. shares inched up Wednesday, trailing the biotech sector after Immunovant released rheumatoid-arthritis data that drew new focus to the same drug class as argenx’s VYVGART franchise. ARGX was trading at $803.67 near the end of the session, up 0.7%. The iShares Nasdaq Biotechnology ETF added 2.1% and SPDR S&P Biotech ETF climbed 3.8%. Shares of Immunovant soared 35.1%. Roivant Sciences, Immunovant’s parent, rose 14.6%, according to market data.
May 20, 2026
Organ-on-a-Chip Technology
·······

Lab Rats No More: How Organ-on-a-Chip Technology is Revolutionizing Drug Testing

Every year, over 100 million animals are used in lab experiments worldwide science.rspca.org.uk. Yet despite this scale of animal testing, around 90% of drug candidates that seem promising in animals end up failing in human trials cen.acs.org. Enter organ-on-a-chip technology – a cutting-edge alternative that aims to mimic human organs on microchips and dramatically improve drug testing without the need for lab animals. These tiny devices, lined with living human cells, can recreate the key functions of hearts, lungs, livers, and more, offering a more human-relevant testing platform. Regulators and scientists are taking notice: new laws and policies are encouraging non-animal methods, companies are racing to develop organ-on-chip systems, and experts herald this approach as a potential game-changer for medicine
August 10, 2025